OXFORD,
England /PRNewswire/ -- After litigating and
negotiating patent infringement claims brought by P2i Ltd against
Europlasma NV relating to P2i United
States patent RE43,651 (the '651 patent), the parties
have resolved their dispute in the United
States without any admission or concession of
wrongdoing or liability on the part of either party. As a result of
the parties' settlement, the US District Court for the Central
District of California dismissed
the case without prejudice.
Under
the terms of the confidential settlement Europlasma NV has (amongst
other things) agreed:
Carl
Francis, P2i's CEO, commented on the settlement, "This
action demonstrates P2i's resolve to protect its valuable patent
portfolio from potential infringers and we are satisfied with the
outcome. We take the protection of our intellectual property rights
very seriously and will continue to enforce our rights
worldwide."
The
parties remain in dispute in other jurisdictions worldwide.
Established as the only credible provider of water repellent
nano-coating technology in mass production, P2i boast monthly
processing volumes that have more than tripled over the last year.
The technology has now been applied to over 100 million electronic
devices worldwide, as smartphone manufacturers seek to improve
reliability and respond to consumer demand to provide essential
protection against water damage.
About
P2i
P2i is
the global leader in liquid repellent nano-coatings, helping
companies around the world give their products improved protection
against damaging elements such as water, oil, sweat and mud. Using
a patented pulsed plasma process, P2i's technology coats products
with an invisible protective coating 1/1000th the
thickness of a human hair. Products P2i has coated include a wide
range of high-value products from mobile phones to technical
clothing, footwear, hearing aids, medical devices, filtration
materials and the nose cones of Formula 1 cars.
Headquartered near Oxford in England,
P2i's market-leading technology is protected by over 175 granted
patents. The company has three laboratory facilities in the
UK, USA and China to
support its continuous development work.
See http://www.p2i.com for more
information.